Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic
The safety of pathogenetic therapy for multiple sclerosis (MS) is a crucial aspect of the therapeutic strategy during the COVID-19 pandemic. Based on our own data, obtained during the study of MS pathogenesis and safety analysis of MS disease-modifying therapies (DMTs), we hereby suggest a classi...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Research Center of Neurology
2022-06-01
|
| سلاسل: | Анналы клинической и экспериментальной неврологии |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/863/634 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|